IDXXIdexx Laboratories

$553.16

The financials

Idexx Laboratories by the numbers

Idexx Laboratories (IDXX) reported revenue of $1.22B in Q2 2026 (quarter ended June 30, 2026), up 9.7% from the same quarter a year earlier. That came with a gross margin of 64% and net income of $338M (28% of revenue). For the full year FY2025, revenue was $4.30B (+10% year on year) and net income $1.06B. Its largest product in 2026-Q1 was Vet Lab Consumables at $413M, 36% of the disclosed total, just ahead of Reference Laboratory Diagnostic And Consulting Services at 34%.

Idexx Laboratories income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Revenue$1.22B$1.11B+9.7%
Gross profit$779M$695M+12%
Operating income$426M$373M+14%
Net income$338M$294M+15%
Diluted EPS$4.27$3.63+18%
Revenue by product, 2026-Q1, as reported to the SEC
ProductRevenueShare
Vet Lab Consumables$413M36%
Reference Laboratory Diagnostic And Consulting Services$386M34%
Veterinary Software Services And Diagnostic Imaging Systems$91M8.0%
Rapid Assay Products$85M7.4%
Recurring$74M6.4%
CAG Diagnostic Capital Instruments$42M3.7%
CAG Diagnostics Service And Accessories$37M3.2%
Systems And Hardware$18M1.6%

Business Segments

Revenue split by product segment, from SEC XBRL filings.

Latest period: Q1 2026Total $1.15B (+4.1%)
CAG Diagnostic Capital Instruments grew +33% year on yearRapid Assay Products +1.1% year on year
  • Vet Lab Consumables$412.6MQoQ +6.4%year on year +20%
  • Reference Laboratory Diagnostic And Consulting Services$386.2MQoQ +6.5%year on year +12%
  • Veterinary Software Services And Diagnostic Imaging Systems$91.3MQoQ +4.0%year on year +12%
  • Rapid Assay Products$84.9MQoQ -4.2%year on year +1.1%
  • Recurring$73.5MQoQ +3.6%year on year +12%
  • CAG Diagnostic Capital Instruments$42.4MQoQ -18%year on year +33%
  • CAG Diagnostics Service And Accessories$36.6MQoQ +7.4%year on year +11%
  • Systems And Hardware$17.8MQoQ +5.7%year on year +12%
Segment sum = 100% of reported consolidated revenue · Latest source: 10-Q filed 2026-05-05, SEC EDGAR